secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001023024-24-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals Q4 revenue up 39.7% YoY; issues 2024 guidance with Cortrophin Gel growth 52-61%
--------------------------------------------------------------------------------

- Q4 net revenues $131.7M (+39.7% YoY); GAAP diluted EPS $0.04; adjusted non-GAAP diluted EPS $1.00.
- Rare Disease (Cortrophin Gel) Q4 revenue $41.7M (+137.3% YoY) with record new patient starts and prescribers.
- Full-year 2023 net revenue $486.8M, adjusted EBITDA $133.8M, operating cash flow $119.0M.
- 2024 guidance: net revenue $520-542M, Cortrophin Gel $170-180M, adjusted EBITDA $135-145M, adjusted EPS $4.26-$4.67.
- Generics segment revenue $71.8M (+23.8% YoY); 11 new products launched in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000024/0001023024-24-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000024/ani-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001023024-24-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer